$12 billion
Pfizer plans on selling 2 billion doses of the vaccine this year, but that demand should subside in coming years so the revenue of Covid-19 vaccine won’t be stable, Pfizer’s CEO Albert Bourla said on an call with analysts and investors. The company expects to continue profiting from it by selling booster doses, including ones required to shield against new variants of the virus, Bourla said. Further, Pfizer is pursuing more avenues to employ the mRNA technology underlying the vaccine, including a flu vaccine and other therapeutic applications.
During the call, Bourla also noted that once the pandemic period is over, the company expects to improve its margins for the vaccine. This would be due to a combination of overall bigger production volumes and an ability to negotiate prices outside an emergency setting.